XML 44 R32.htm IDEA: XBRL DOCUMENT v3.23.1

Segment, Geographical and Other Revenue Information (Tables)

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Schedule of segment reporting

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):

			Three Months Ended March 31, 2023																		Three Months Ended March 31, 2022
			Performance Enzymes						Novel Biotherapeutics						Total						Performance Enzymes						Novel Biotherapeutics						Total
Revenues:
Product revenue			$	8,364					$	—					$	8,364					$	30,690					$	—					$	30,690
Research and development revenue			1,122						3,496						4,618						2,409						2,241						4,650
Total revenues			9,486						3,496						12,982						33,099						2,241						35,340
Costs and operating expenses:
Cost of product revenue			4,521						—						4,521						8,521						—						8,521
Research and development (1)			8,099						7,312						15,411						6,122						12,346						18,468
Selling, general and administrative (1)			2,798						951						3,749						3,541						720						4,261
Restructuring charges			—						72						72						—						—						—
Total segment costs and operating expenses			15,418						8,335						23,753						18,184						13,066						31,250
Income (loss) from operations			$	(5,932)					$	(4,839)					(10,771)						$	14,915					$	(10,825)					4,090
Corporate costs (2)															(10,364)																		(11,205)
Unallocated depreciation and amortization															(1,466)																		(1,232)
Loss before income taxes															$	(22,601)																	$	(8,347)

(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.

(2) Corporate costs include unallocated selling, general and administrative expenses, interest income, and other expense, net.

The following table provides stock-based compensation expense included in income (loss) from operations (in thousands):

			Three Months Ended March 31,
			2023																								2022
			Performance Enzymes						Novel Biotherapeutics						Corporate cost						Total						Performance Enzymes						Novel Biotherapeutics						Corporate cost						Total
Stock-based compensation			$	1,035					$	413					$	1,361					$	2,809					$	1,690					$	410					$	1,738					$	3,838

Schedule of customers that contributed 10% or more of total accounts receivable

Significant Customers

Customers that each accounted for 10% or more of our total revenues were as follows:

			Percentage of Total Revenues for the
			Three Months Ended March 31,
			2023						2022
Customer A			*						61		%
Customer B			23		%				*
Customer C			14		%				*
Customer D			13		%				*
Customer E			10		%				*
* Percentage was less than 10%

Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:

			Percentage of Accounts Receivables as of
			March 31, 2023						December 31, 2022
Customer A			*						53		%
Customer B			21		%				*
Customer C			11		%				10		%
Customer F			14		%				*
Customer G			12		%				*
* Percentage was less than 10%

Schedule of revenues by geographical area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):

			Three Months Ended March 31,
			2023						2022
Revenues:
Americas			$	2,584					$	3,732
EMEA			3,089						4,127
APAC			7,309						27,481
Total revenues			$	12,982					$	35,340

Schedule of long-lived assets by geographical area

Identifiable long-lived assets by location was as follows (in thousands):

			March 31, 2023						December 31, 2022
United States			$	61,622					$	61,877

Schedule of intangible assets and goodwill

Identifiable goodwill by reporting unit was as follows (in thousands):

			As of March 31, 2023 and December 31, 2022
			Performance Enzymes						Novel Biotherapeutics						Total
Goodwill			$	2,463					$	778					$	3,241

X

- Definition

Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Name:	us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration